Generic Name: etonogestrel
Brand Name: Nexplanon
Manufacturer: Merck Canada Inc.
Indications: Prevention of pregnancy
Manufacturer Requested Reimbursement Criteria1: Indicated for the prevention of pregnancy for up to 3 years
Submission Type: New
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient input open | May 06, 2020 |
| Call for patient input closed | June 25, 2020 |
| Clarification: - No patient input submission received | |
| Submission received | June 03, 2020 |
| Clarification: Submission was previously withdrawn and has been refiled by the sponsor | |
| Submission accepted | June 17, 2020 |
| Review initiated | June 18, 2020 |
| Draft CADTH review report(s) provided to sponsor for comment | July 31, 2020 |
| Deadline for sponsors comments | August 12, 2020 |
| CADTH responses on draft review report(s) provided to sponsor | September 03, 2020 |
| Expert committee meeting (initial) | September 16, 2020 |
| Draft recommendation issued | September 28, 2020 To September 30, 2020 |